Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) Dividend History

1111 Kane Concourse, Bay Harbor Islands, FL, 33154
Phone: 781-652-4500
Website: https://www.fortressbiotech.com

Dividend History

Pay Date	Amount	Ex Dividend Date	Record Date
June 30, 2024	$0.20	06/14/2024	06/15/2024
May 31, 2024	$0.20	05/14/2024	05/15/2024
April 30, 2024	$0.20	04/12/2024	04/15/2024
March 31, 2024	$0.20	03/14/2024	03/15/2024
February 29, 2024	$0.20	02/14/2024	02/15/2024
January 31, 2024	$0.20	01/11/2024	01/15/2024
December 31, 2023	$0.20	12/14/2023	12/15/2023
November 30, 2023	$0.20	11/14/2023	11/15/2023
October 31, 2023	$0.20	10/12/2023	10/15/2023
September 30, 2023	$0.20	09/14/2023	09/15/2023
August 31, 2023	$0.20	08/14/2023	08/15/2023
July 31, 2023	$0.20	07/13/2023	07/15/2023
June 30, 2023	$0.20	06/14/2023	06/15/2023
May 31, 2023	$0.20	05/12/2023	05/15/2023
April 30, 2023	$0.20	04/13/2023	04/15/2023
March 31, 2023	$0.20	03/14/2023	03/15/2023
February 28, 2023	$0.20	02/14/2023	02/15/2023
January 31, 2023	$0.20	01/12/2023	01/15/2023
December 31, 2022	$0.20	12/14/2022	12/15/2022
November 30, 2022	$0.20	11/14/2022	11/15/2022
October 31, 2022	$0.20	10/13/2022	10/15/2022
September 30, 2022	$0.20	09/14/2022	09/15/2022
August 31, 2022	$0.20	08/12/2022	08/15/2022
July 31, 2022	$0.20	07/14/2022	07/15/2022
June 30, 2022	$0.20	06/14/2022	06/15/2022
May 31, 2022	$0.20	05/12/2022	05/15/2022
April 30, 2022	$0.20	04/13/2022	04/15/2022
March 31, 2022	$0.20	03/14/2022	03/15/2022
February 28, 2022	$0.20	02/14/2022	02/15/2022
January 31, 2022	$0.20	01/13/2022	01/15/2022
December 31, 2021	$0.20	12/14/2021	12/15/2021
November 30, 2021	$0.20	11/12/2021	11/15/2021
October 30, 2021	$0.20	10/14/2021	10/15/2021
September 30, 2021	$0.20	09/14/2021	09/15/2021
August 30, 2021	$0.20	08/12/2021	08/15/2021
July 30, 2021	$0.20	07/14/2021	07/15/2021
June 30, 2021	$0.20	06/14/2021	06/15/2021
May 30, 2021	$0.20	05/13/2021	05/15/2021
April 30, 2021	$0.20	04/14/2021	04/15/2021
March 31, 2021	$0.20	03/12/2021	03/15/2021
February 28, 2021	$0.20	02/11/2021	02/15/2021
January 31, 2021	$0.20	01/14/2021	01/15/2021
December 31, 2020	$0.20	12/14/2020	12/15/2020
November 30, 2020	$0.20	11/12/2020	11/15/2020
October 31, 2020	$0.20	10/14/2020	10/15/2020
September 30, 2020	$0.20	09/14/2020	09/15/2020
August 31, 2020	$0.20	08/20/2020	08/21/2020
July 31, 2020	$0.20	07/17/2020	07/20/2020
June 30, 2020	$0.59	06/12/2020	06/15/2020
March 31, 2020	$0.59	03/13/2020	03/16/2020
December 31, 2019	$0.59	12/12/2019	12/15/2019
September 30, 2019	$0.59	09/12/2019	09/15/2019
July 01, 2019	$0.59	06/13/2019	06/15/2019
March 31, 2019	$0.59	03/14/2019	03/15/2019
December 31, 2018	$0.59	12/13/2018	12/15/2018
September 30, 2018	$0.59	09/13/2018	09/15/2018
June 30, 2018	$0.59	06/14/2018	06/15/2018
March 30, 2018	$0.59	03/14/2018	03/15/2018

Dividends Summary

Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock has issued 58 dividend payments over the past 6 years
The most recent dividend was paid 342 days ago, on June 30, 2024
The first recorded dividend was paid on March 30, 2018
The highest dividend payout was $0.59 per share
The average dividend over this 6 year span is $0.26 per share
Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock has decreased its dividend payments by 66.67% since 2018

Company News

Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics

Fortress Biotech announced the closing of the sale of its subsidiary Checkpoint Therapeutics to Sun Pharmaceutical Industries Limited. The transaction will generate approximately $28 million for Fortress and a 2.5% royalty on net sales of Checkpoint's FDA-approved drug UNLOXCYT.

Benzinga

Featured Companies: CKPT FBIO
Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference

Fortress Biotech, an innovative biopharmaceutical company, announced the FDA approval of its drug Emrosi for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway. The company also announced a strategic collaboration with Partex NV to accelerate asset identification and evaluation using Partex's proprietary AI platform.

GlobeNewswire Inc.

Featured Companies: FBIO
Mustang Bio Announces Closing of $8 Million Public Offering

Mustang Bio, a clinical-stage biopharmaceutical company, announced the closing of a public offering of common stock and warrants, raising approximately $8 million. The company plans to use the proceeds for working capital and general corporate purposes.

GlobeNewswire Inc.

Featured Companies: FBIO MBIO
Mustang Bio Announces Pricing of $8 Million Public Offering

Mustang Bio, a clinical-stage biopharmaceutical company, announced the pricing of a public offering of $8 million, which it plans to use for working capital and general corporate purposes.

Benzinga

Featured Companies: FBIO MBIO
Mustang Bio Announces Pricing of $8 Million Public Offering

Mustang Bio, a clinical-stage biopharmaceutical company, announced the pricing of a public offering of common stock, Series C-1 warrants, and Series C-2 warrants, raising approximately $8 million in gross proceeds.

GlobeNewswire Inc.

Featured Companies: FBIO MBIO

Dividend data last updated 06/07/2025 20:27:53 UTC